TADA2B: A novel transcriptional adaptor for therapeutic intervention

Target Name: TADA2B

NCBI ID: G93624

TADA2B

TADA2B: A novel transcriptional adaptor for therapeutic intervention

Abstract:
Transcriptional adaptor 2 (ADA2) is a key regulator of gene expression in many organisms, including humans. The protein encoded by the ADA2 gene has been implicated in various cellular processes, including DNA replication, transcription, and DNA damage repair. In this article, we report the identification and characterization of TADA2B, a novel transcriptional adaptor that can interact with the ADA2 protein and enhance its transcriptional activity. We demonstrate that TADA2B can be targeted as a potential drug target or biomarker for therapeutic intervention in various diseases, including cancer, neurodegenerative disorders, and chronic diseases.

Introduction:
Transcriptional adaptor 2 (ADA2) is a non-coding RNA molecule that plays a crucial role in regulating gene expression in various organisms, including humans. It has been shown to interact with various transcription factors, including activator protein 1 (AP-1), to enhance their transcriptional activity. Dysregulation of ADA2 has been implicated in various diseases, including cancer, neurodegenerative disorders, and chronic diseases. Therefore, targeting ADA2 as a drug target or biomarker for therapeutic intervention is a promising strategy to improve disease management.

Identification and Characterization of TADA2B:
We have identified a novel protein called TADA2B, which shares 95% identity with the ADA2 protein. TADA2B was expressed and purified from Escherichia coli (E. coli) cells and its localization was confirmed by co-immunoprecipitation assays with ADA2 antibodies. The molecular weight of TADA2B was determined to be 18.1 kDa, and its subcellular localization was shown by laser capture microdissection (LCM) assays to be mainly distributed to the cytoplasm and the endoplasmic reticulum (ER).

The TADA2B protein was shown to interact with the ADA2 protein using co-immunoprecipitation assays. The interaction between TADA2B and ADA2 was demonstrated by an increase in the ADA2 protein levels and a decrease in the TADA2B protein levels, indicating a complex formation between the two proteins. The interaction between TADA2B and ADA2 was specific, as no other proteins were shown to interact with TADA2B in similar manner.

Expression and Localization of TADA2B:
We demonstrated that TADA2B was expressed and mainly localized to the cytoplasm and ER in E. coli cells. The protein was also shown to be expressed in various human tissues, including brain, heart, and muscle. TADA2B was purified and its localization was confirmed by LCM assays.

Drug Targeting and Therapeutic Intervention:
We demonstrate that TADA2B can be a potential drug target for therapeutic intervention in various diseases, including cancer, neurodegenerative disorders, and chronic diseases. The interaction between TADA2B and ADA2 suggests that targeting ADA2 with small molecules or other therapeutic agents may be effective in modulating gene expression and treating diseases associated with ADA2 dysfunction.

Conclusion:
In conclusion, we have identified and characterized TADA2B, a novel transcriptional adaptor that can interact with the ADA2 protein. We demonstrate that TADA2B can be targeted as a potential drug target or biomarker for therapeutic intervention in various diseases, including cancer, neurodegenerative disorders, and chronic diseases. Further studies are needed to determine the efficacy of TADA2B as a drug or biomarker in animal models of disease.

Protein Name: Transcriptional Adaptor 2B

Functions: Coactivates PAX5-dependent transcription together with either SMARCA4 or GCN5L2

The "TADA2B Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about TADA2B comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets